Datopotamab Deruxtecan, often abbreviated as DATO, represents a important advancement regarding targeted cancer care. This novel antibody-drug conjugate joins an monoclonal antibody specifically targeting HER2 https://socialrus.com/story24430202/datopotamab-deruxtecan-an-encouraging-antibody-drug-compound